We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Point-of-Care Immunoassay Analyzer on Display at AACC Annual Meeting

By LabMedica International staff writers
Posted on 02 Aug 2016
Image: The LABGEO IB10 chemistry analyzer (Photo courtesy of Samsung / Thermo Fisher Scientific).
Image: The LABGEO IB10 chemistry analyzer (Photo courtesy of Samsung / Thermo Fisher Scientific).
A small, simple to use basic immunoassay analyzer designed for point-of-care (POC) settings is available for inspection in the Thermo Fisher Scientific (Fremont, CA, USA) Booth 2145 at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

The Samsung LABGEO IB10 chemistry analyzer is the result of the partnership between Samsung (Suwon, South Korea) and Thermo Fisher Scientific.

The LABGEO IB10 is a small, simple to use basic immunoassay analyzer designed for POC settings. It was designed to measure TnI, D-Dimer, NT-proBNP, Myoglobulin, CK-MB, TSH, HCG, and PCT (Procalcitonin) within 20 minutes from a single use cartridge. Each cartridge includes calibration data, lot number, analyte listing, and expiration data.

The broad menu, short turn around time, and simplicity of the LABGEOIB10 make it ideal for satellite laboratories, physician offices, remote locations, and other settings where speed and convenience can improve productivity and patient compliance to treatment goals.

Related Links:
Thermo Fisher Scientific
AACC Annual Meeting & Clinical Lab Expo
Samsung
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
All-in-One Molecular System
AIO M160

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG